These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 37267211)

  • 1. Efficacy of Topical 0.05% Cyclosporine A for Ocular Surface Disease Related to Topical Anti-Glaucoma Medications.
    Kim JG; An JH; Cho SY; Lee CE; Shim KY; Jun JH
    J Ocul Pharmacol Ther; 2023 Jul; 39(6):389-397. PubMed ID: 37267211
    [No Abstract]   [Full Text] [Related]  

  • 2. Ocular Surface Disease in Patients under Topical Treatment for Glaucoma.
    Pérez-Bartolomé F; Martínez-de-la-Casa JM; Arriola-Villalobos P; Fernández-Pérez C; Polo V; García-Feijoó J
    Eur J Ophthalmol; 2017 Nov; 27(6):694-704. PubMed ID: 28497458
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Topical cyclosporine to control ocular surface disease in patients with chronic glaucoma after long-term usage of topical ocular hypotensive medications.
    Saini M; Dhiman R; Dada T; Tandon R; Vanathi M
    Eye (Lond); 2015 Jun; 29(6):808-14. PubMed ID: 25857609
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of Long-Term Topical Antiglaucoma Medication Use on the Ocular Surface.
    Awe OO; Onakpoya OH; Adeoye AO
    Niger Med J; 2020; 61(4):184-188. PubMed ID: 33284876
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tear neuromediators in eyes on chronic topical antiglaucoma therapy with and without BAK preservatives.
    Murugesan V; Dwivedi R; Saini M; Gupta V; Dada T; Vivekanandhan S
    Br J Ophthalmol; 2021 Jan; 105(1):141-148. PubMed ID: 31383648
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ocular Surface Disease in Glaucoma: Effect of Polypharmacy and Preservatives.
    Ramli N; Supramaniam G; Samsudin A; Juana A; Zahari M; Choo MM
    Optom Vis Sci; 2015 Sep; 92(9):e222-6. PubMed ID: 25730335
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of topical cyclosporine 0.05% and osmoprotective lubricating eye drops in treating dry eye disease and inflammation.
    Mullick R; Annavajjhala S; Thakur P; Mohapatra A; Shetty R; D'Souza S
    Indian J Ophthalmol; 2021 Dec; 69(12):3473-3477. PubMed ID: 34826977
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical audit examining the impact of benzalkonium chloride-free anti-glaucoma medications on patients with symptoms of ocular surface disease.
    Goldberg I; Graham SL; Crowston JG; d'Mellow G;
    Clin Exp Ophthalmol; 2015 Apr; 43(3):214-20. PubMed ID: 25196488
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Risk factors to develop ocular surface disease 
in treated glaucoma or ocular hypertension patients.
    Rossi GC; Pasinetti GM; Scudeller L; Raimondi M; Lanteri S; Bianchi PE
    Eur J Ophthalmol; 2013; 23(3):296-302. PubMed ID: 23335308
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Assessment of ocular surface disease in glaucoma patients with benzalkonium chloride-preserved latanoprost eye drops: a short-term longitudinal study.
    Su CC; Lee YC; Lee PRC
    Graefes Arch Clin Exp Ophthalmol; 2021 May; 259(5):1243-1251. PubMed ID: 33433642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Topical Cyclosporine Pretreatment of Ocular Surface in Allogeneic Hematopoietic Stem Cell Transplant Recipients.
    Chun YH; Beak JU; Kim HS; Na KS
    J Ocul Pharmacol Ther; 2018 Nov; 34(9):628-632. PubMed ID: 30289329
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of Topical Cyclosporine and Diquafosol Treatment in Dry Eye.
    Yang JM; Choi W; Kim N; Yoon KC
    Optom Vis Sci; 2015 Sep; 92(9):e296-302. PubMed ID: 26107023
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Corneal sensitivity in patients treated medically for glaucoma or ocular hypertension].
    Van Went C; Alalwani H; Brasnu E; Pham J; Hamard P; Baudouin C; Labbé A
    J Fr Ophtalmol; 2011 Dec; 34(10):684-90. PubMed ID: 22093372
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prevalence of ocular surface disease in glaucoma patients.
    Leung EW; Medeiros FA; Weinreb RN
    J Glaucoma; 2008 Aug; 17(5):350-5. PubMed ID: 18703943
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ocular Surface Disease in Glaucoma Patients Randomized to Benzalkonium Chloride-Containing Latanoprost and Preservative-Free Bimatoprost.
    Wu JH; Wang TH; Huang JY; Su CC
    J Ocul Pharmacol Ther; 2021 Dec; 37(10):556-564. PubMed ID: 34610257
    [No Abstract]   [Full Text] [Related]  

  • 16. Assessment of Corneal Changes Associated with Topical Antiglaucoma Therapy Using in vivo Confocal Microscopy.
    Baghdasaryan E; Tepelus TC; Vickers LA; Huang P; Chopra V; Sadda SR; Lee OL
    Ophthalmic Res; 2019; 61(1):51-59. PubMed ID: 29627838
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluation of the effect of topical tacrolimus 0.03% versus cyclosporine 0.05% in the treatment of dry eye secondary to Sjogren syndrome.
    Moawad P; Shamma R; Hassanein D; Ragab G; El Zawahry O
    Eur J Ophthalmol; 2022 Jan; 32(1):673-679. PubMed ID: 33530719
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prospective Randomized Trial Comparing Efficacy of Topical Loteprednol Etabonate 0.5% Versus Cyclosporine-A 0.05% for Treatment of Dry Eye Syndrome Following Hematopoietic Stem Cell Transplantation.
    Boynton GE; Raoof D; Niziol LM; Hussain M; Mian SI
    Cornea; 2015 Jul; 34(7):725-32. PubMed ID: 25850708
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Multicenter, Randomized, Double-Blind Evaluation of the Efficacy of TJO-087 Versus 0.05% Cyclosporine A in Moderate to Severe Dry Eye.
    Eom Y; Yoon KC; Kim HK; Song JS; Hyon JY; Kim HM
    J Ocul Pharmacol Ther; 2023; 39(1):27-35. PubMed ID: 36450107
    [No Abstract]   [Full Text] [Related]  

  • 20. Effect of Switching to Travoprost Preserved With SofZia in Glaucoma Patients With Chronic Superficial Punctate Keratitis While Receiving BAK-preserved Latanoprost.
    Aihara M; Ikeda Y; Mizoue S; Arakaki Y; Kita N; Kobayashi S;
    J Glaucoma; 2016 Jun; 25(6):e610-4. PubMed ID: 25967526
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.